Mesuximide
Chemical compound
- N03AD03 (WHO)
- US: ℞-only
28–38 hours (active metabolite)
- (RS)-1,3-dimethyl-3-phenyl-pyrrolidine-2,5-dione
- 77-41-8 Y
- 6476
- 7228
- DB05246 N
- 6231 Y
- 0G76K8X6C0
- D00404 Y
- ChEMBL697 Y
- DTXSID5023293
- Interactive image
- O=C2N(C(=O)CC2(c1ccccc1)C)C
- InChI=1S/C12H13NO2/c1-12(9-6-4-3-5-7-9)8-10(14)13(2)11(12)15/h3-7H,8H2,1-2H3 Y
- Key:AJXPJJZHWIXJCJ-UHFFFAOYSA-N Y
Mesuximide (or methsuximide, methosuximide) is a succinimide anticonvulsant medication. It is sold as a racemate by Pfizer under the tradenames Petinutin (Switzerland)[1] and Celontin (United States).[2] The therapeutic efficacy of methosuximide is largely due to its pharmacologically active metabolite, N-desmethylmethosuximide, which has a longer half-life and attains much higher plasma levels than its parent.[3]
Medical use
is indicated for the control of absence seizures that are refractory to other drugs.[2]
References
- ^ Pfizer AG (2005). "Petinutin (Mésuximide)". Official Pfizer AG Website (in French). Archived from the original on April 22, 2005. Retrieved August 21, 2006.
- ^ a b Pfizer Inc. (2008). "Celontin (methsuximide capsules, USP)". Official Pfizer Inc. Website. Retrieved November 21, 2014.
- ^ Porter RJ, Penry JK, Lacy JR, Newmark ME, Kupferberg HJ (November 1979). "Plasma concentrations of phensuximide, methsuximide, and their metabolites in relation to clinical efficacy". Neurology. 29 (11): 1509–13. doi:10.1212/wnl.29.11.1509. PMID 116142. S2CID 43643797.
- v
- t
- e
modulators
CA inhibitors |
|
---|---|
Others |
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
This anticonvulsant-related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e